Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate AgomAb Therapeutics NV before investing.

In this article, we go over a few key elements for understanding AgomAb Therapeutics NV’s stock price such as:

• AgomAb Therapeutics NV’s current stock price and volume
• Why AgomAb Therapeutics NV’s stock price changed recently
• Upgrades and downgrades for AGMB from analysts
• AGMB’s stock price momentum as measured by its relative strength

About AgomAb Therapeutics NV (AGMB)

Before we jump into AgomAb Therapeutics NV’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Want to learn more about AgomAb Therapeutics NV’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about AgomAb Therapeutics NV.

AgomAb Therapeutics NV’s Stock Price as of Market Close

As of September 10, 2026, 4:00 PM, CST, AgomAb Therapeutics NV’s stock price was $13.940.

AgomAb Therapeutics NV is down 6.82% from its previous closing price of $14.960.

During the last market session, AgomAb Therapeutics NV’s stock traded between $13.750 and $16.400. Currently, there are approximately 0.64 million shares outstanding for AgomAb Therapeutics NV.

AgomAb Therapeutics NV’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

AgomAb Therapeutics NV Stock Price History

AgomAb Therapeutics NV’s (AGMB) price is currently up 5.85% so far this month.

During the month of September, AgomAb Therapeutics NV’s stock price has reached a high of $16.500 and a low of $12.620.

Over the last year, AgomAb Therapeutics NV has hit prices as high as $17.820 and as low as $8.750.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused AgomAb Therapeutics NV Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 10, 2026, there were analysts who downgraded AgomAb Therapeutics NV’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate AgomAb Therapeutics NV’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on AgomAb Therapeutics NV’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about AgomAb Therapeutics NV (AGMB) by visiting AAII Stock Evaluator.

Relative Price Strength of AgomAb Therapeutics NV

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 10, 2026, AgomAb Therapeutics NV has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how AgomAb Therapeutics NV is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

AgomAb Therapeutics NV Stock Price: Bottom Line

As of September 10, 2026, AgomAb Therapeutics NV’s stock price is $13.940, which is down 6.82% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like AgomAb Therapeutics NV stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.